An agreement between Boehringer Ingelheim, a global pharmaceutical group of companies, and Pfizer would transfer certain assets of Wyeth Pharmaceutical’s Fort Dodge Animal Health. This is slated to happen early in the fourth quarter after the global Pfizer-Wyeth merger closes, pending anti-trust clearance.


The addition of the Fort Dodge product portfolio to Boehringer Ingelheim would grow the company in the U.S., Canada, Australia, some European countries and South Africa with the acquisition of several animal vaccine lines and pharmaceuticals. The deal would also include a manufacturing and research facility located in Fort Dodge, Iowa.